Balogh, ..., Mark DeMario,Richard B. Gaynor, Lakshmi Srinivasan Correspondence richard.gaynor@biontech.us (R.B.G.), lakshmi.srinivasan1@external.biontech.us (L.S.) In brief In a Phase Ib clinical study, Awad et al. demonstrate feasibility, safety, andimmunogenicity of NEO-PV-01 pluschemotherapy and PD-1 inhibition inadvanced NSCLC as a ﬁrst-line treat-ment. Neoantigen-speciﬁc CD4 +T cells have an activated effector phenotype.CD4 +T cells inﬁltrate tumors post-vacci- nation and induce epitope spread to otherneoantigens such as mutant KRAS . Awad et al., 2022, Cancer Cell 40, 1010–1026 September 12, 2022 ª2022 Elsevier Inc. https://doi.org/10.1016/j.ccell.2022.08.003 ll Article Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as ﬁrst-linetreatment for non-squamous non-small cell lungcancer Mark M. Awad,1Ramaswamy Govindan,2Kristen N.